**Review**

**General Anesthetics in Cancer Surgery: Can Anesthesiologists Help the Patient with More than a Safe Sleep**

John Michael Bonvini 1,2

1 Department of Anesthesiology, Ars Medica Clinic, Via Grumo, 16, 6929 Gravesano, Switzerland; johnmichael.bonvini@uzh.ch
2 University of Zurich, Ramistrasse, 71, 8006 Zurich, Switzerland

**Abstract:** Most patients suffering from neoplastic diseases will at some point during their illness be approached surgically. Surgery itself may be unfortunately responsible for tumor proliferation and metastatic spread. With the perioperative period increasingly becoming a focus of research in anesthesia, anesthesiologists have looked at the chance to influence cancer progression based on their choice of anesthesia regimen and strategy. Many anesthetic agents have been investigated for their potential impact on the course of cancer disease. There is an abundance of retrospective studies and very few prospective ones that tackled this issue. The aim of this article is to review the current state of the evidence on general anesthesia involving volatile and intravenous agents as substrates, focusing on halogenated inhalational agents and propofol, to guide clinical decision making in assessments of the best practice for perioperative management of cancer surgery.

**Keywords:** cancer surgery; general anesthetics; propofol; volatile anesthetics

---

**1. Introduction**

Neoplastic disease is a one of the major causes of mortality. Worldwide, over 19 million new cancer cases and 10 million cancer-related deaths were estimated for 2020, and for the first-time, female breast cancer, with 2.3 million new cases (11.7% of all new cases), surpassed lung cancer (11.4%), followed by colorectal disease (10%) and prostate cancer (7.3%) [1].

Most solid tumors are at some stage approached surgically, and over 80% of new cancer cases will require surgery at least once if not several times during the course of the disease [2].

General anesthetics (GA) are used to facilitate surgical procedures and can be generally divided in volatile (inhalational) and intravenous agents. Both induce, as a primary effect, unconsciousness in the patient. The exact mechanism of actions, even after over decades of safe clinical use, are still being investigated [3].

Perioperative medicine has become a major focus for modern anesthesiologists [4] and has sparked interest as a possible anesthesiologic strategy in the surgical management of cancer patients since it is well known that, all over the world, drugs used in operating theaters to induce unconsciousness on a daily basis have more effects than they are primarily used for.

Among these many effects, of particular interest are the effects on extracellular matrix (ECM)-degrading proteins such as matrix metalloproteinases (MMP). These proteins are potent remodelers of the ECM, and their abnormal expression bears the potential of enhancing metastatic disease [5]. The effects of GA on microRNAs (MiR) are also being increasingly investigated. MiR are small non-coding RNAs that modulate gene expression and might be heavily dysregulated in cancerous disease [6].
2. Volatile Anesthetics

Volatile anesthetics have shown a beneficial effect in ischemia reperfusion injury [7–9]. Through the suppression of NK cells, macrophages, and neutrophils, they modulate the innate immune response as well as the adaptive immune system by increasing lymphocyte apoptosis while inhibiting their proliferation [10–12]. Unfortunately, these same effects can, however, be detrimental in other settings, such as in general anesthesia for cancer surgery [10].

The results of in vitro studies using volatile anesthetics in cancer cells are heterogeneous. The in vitro exposure of renal carcinoma cells to sevoflurane increased cancer resistance to the chemotherapeutic agent cisplatin, and increased cell migration and viability [13]. Interestingly, in the same in vitro setting but using non-small cell lung carcinoma (NSCLC) cells, sevoflurane reduced the cell viability and increased the sensitivity to cisplatin without increasing cell migration [13].

Exposure of human ovarian carcinoma cells to halogenated inhalational anesthetics (isoflurane, sevoflurane, and desflurane) enhanced the expression of numerous genes associated with metastatic proliferation [14] and, with isoflurane, led to an increase in markers associated with malignant capabilities such as cell proliferation, migration, as well as angiogenesis [15]. In contrast, volatile agents have been shown to reduce ECM breakdown through the down-regulation of Matrix metalloproteinase 9 (MMP-9), thus reducing the metastatic cancer cell potential [16].

3. Propofol

The intravenous general anesthetic propofol has also been investigated regarding its potential effects on cancer cells [17].

In human pancreatic cancer cells, propofol has been found to decrease cell proliferation and migration as well to increase apoptosis rates, possibly through the upregulation of microRNA miR-133a [18]. Propofol also potentiated growth inhibition and apoptosis induced by the chemotherapeutic agent gemcitabine and downregulated NF-kB DNA binding activity, hence counteracting its anti-apoptotic activity [19].

In ovarian cancer cells, it modulated microRNA miR-let-7i, inhibited cell proliferation, and increased apoptosis [20]. Its activation of miR-9 was associated with an inhibition of metalloprotease MMP-9 involved in the degradation of the extracellular matrix; was associated with the invasive potential of cancer cells; and modulated the NF-kB pathway, thus enhancing apoptosis [21]. Some ovarian cell lines show different resistances to chemotherapeutic agents, one of which is paclitaxel. Interestingly, propofol inhibited cell invasion and proliferation in paclitaxel-resistant but not in paclitaxel-sensitive cell lines, while apoptosis was enhanced in both sensitive and resistant cell lines [22].

Looking at hepatocellular carcinoma (HCC), propofol also efficiently inhibited the growth of HCC cells and activated both caspase-8 and caspase-9, suggesting that both intrinsic and extrinsic pathways induce apoptosis. This is thought to occur through the modulation of miR-199a microRNA [23]. Propofol also reduced the adhesion ability of HCC cells and downregulated the expression and activity of MMP-9 associated with the facilitation of HCC cell invasion in neighboring tissues [24].

In lung adenocarcinoma cells, the inhibition of MMPs via propofol also resulted in diminished cell invasion and migration [25]. Similarly, in non-small cell lung cancer, propofol showed a reduction in the mRNA expression of various MMPs as well as the inhibition of cell adhesion motility and migration [26]. Propofol in NSCLC cells effectively suppressed the effects of inflammation, which is associated in the tumor microenvironment, and promotes cancer aggressiveness, together with a significant reduction in Hypoxia inducible factor 1 alpha, the high expression of which is associated with poor prognosis [26]. Furthermore, propofol was also found to suppress NSCLC cell growth, to accelerate apoptosis through the miR-21/PTEN/AKT pathway in vitro, and to effectively inhibited tumor growth in vivo in an animal model [27].
On the other hand, recent work has shown that propofol promoted tumor metastasis, probably through its affinity for the GABAAR receptor, downregulating the expression of the tripartite motif protein family TRIM21 and subsequently increasing the expression of the Src protein [28]. It is in fact known that the expression of Src is associated with the metastatic potential of cancer cells since it promotes the epithelial–mesenchymal transition that occurs during tumor extravasation [29] and its inhibition suppresses the adhesion of lung cancer cells [30].

In breast cancer, propofol has been shown to significantly downregulate microRNA miR-24, the overexpression of which promotes cell proliferation and inhibits apoptosis [31]. On the other hand, the GABA agonism of propofol has been shown to increase the migration of breast carcinoma cells by reorganizing the actin cytoskeleton [32] and its antioxidant properties have been associated with increasing cell proliferation, through the inhibition of p53, a recognized tumor-suppressor gene and up-regulator of cell apoptosis [33].

4. Clinical Studies

There is an abundance of retrospective clinical trials assessing potential differences in general anesthesia regimes in cancer surgery, with many of them favoring the use of propofol, e.g., as in colon cancer [34], esophageal cancer [35], hepatectomy for HCC [36], radical prostatectomy [37], and breast cancer [38]. In other retrospective studies where no difference in overall mortality was found, a lower recurrence rate was associated with the use of propofol [39,40], while no difference either in overall or recurrence-free survival was found in NLCLC [41] and in breast cancer [42,43].

Since immunomodulation plays a significant role in immunosuppression, inflammation, and cancer recurrence [44], a recent meta-analysis looked at interleukin (IL) 6, IL-10, tumor necrosis factor, and C-reactive protein as surrogate markers for perioperative inflammation. The authors found no differences between the two general anesthetic techniques, suggesting no definitive impact of the choice of general anesthetic on the inflammatory response and its associated cancer aggressiveness [26,45].

On the other hand, in a large retrospective study over a three-year period, looking at long-term survival in patients, Wigmore et al. found an increased hazard ratio (1.46, 95% CI 1.29 to 1.66) for patients undergoing surgery under general inhalational anesthesia [46]. Similarly, Yap et al. suggested in their systematic review that propofol-based general anesthesia may be associated with better recurrence free and overall survival when compared with volatile anesthetics [47], acknowledging, however, that the inherent limitations of the 10 studies included in their review commanded larger, well-designed prospective studies to corroborate these findings.

In fact, very few prospective clinical studies have tackled the question of whether propofol clinically offers benefits over inhalational anesthesia in cancer surgery.

Oh et al. hypothesized that propofol would be less immunosuppressive than sevoflurane in breast surgery; looking at regulatory T cells, Oh et al. found that there was no difference in the tumor-cell-killing capabilities of natural killer- and cytotoxic T-cells [48].

Yan et al. showed in patients undergoing breast cancer surgery that vascular endothelial growth factor (VEGF) serum concentrations where higher after general anesthesia with sevoflurane when compared with propofol but, despite the increase in this angiogenesis promoting marker, found no difference in the recurrence-free survival when comparing the two anesthesiologic strategies [49].

In metastatic disease, one factor affecting the distant spread of the disease is the number and characteristics of circulating tumor cells (CTC) [50–53]. In a recent work, the influence of the choice of general anesthetic on the number of CTCs in vivo was assessed in women undergoing surgery for breast cancer as an independent prognostic factor. In a parallel controlled trial, et al. randomized 210 women undergoing primary breast cancer surgery to receive either sevoflurane or propofol based general anesthesia. Hovaguimian et al. found no difference in the median number of circulating tumor cells assessed at 0, 48, and 72 h. Interestingly, they noted that administrating sevoflurane led to a significant
increase in the maximal tumor cell counts postoperatively, but no association was found between circulating tumor cell counts and natural killer cell activity [54].

5. Conclusions

The question of which anesthesia regimen is better suited for patients undergoing cancer surgery cannot be definitively answered without further prospective clinical research. Most of the evidence at this time seems to favor propofol, but most probably, this will not become a “magic cancer bullet”. A thorough evaluation of the risk–benefit profiles of inhalational/intravenous strategies for individual patients is key in choosing a tailored anesthesiologic regimen.

After all, informed, individual, and precise perioperative management is the best help an anesthesiologist can offer its patients for a safe sleep.

Funding: This research received no external funding.

Acknowledgments: The author would like to thank Beatrice Beck-Schimmer for her most valuable suggestions and fruitful discussions on this important topic.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]

2. Sullivan, R.; Alatise, O.I.; Anderson, B.O.; Audisio, R.; Autier, P.; Aggarwal, A.; Balch, C.; Brennan, M.F.; Dare, A.; D’Cruz, A.; et al. Global cancer surgery: Delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015, 16, 1193–1224. [CrossRef]

3. Sonner, J.M.; Cantor, R.S. Molecular mechanisms of drug action: An emerging view. Annu. Rev. Biophys. 2013, 42, 143–167. [CrossRef] [PubMed]

4. Beutler, S.; McEvoy, M.D.; Ferrari, L.; Vetter, T.R.; Bader, A.M. The Future of Anesthesia Education: Developing Frameworks for Perioperative Medicine and Population Health. Anesth. Analg. 2020, 130, 1103–1108. [CrossRef] [PubMed]

5. Cabral-Pacheco, G.A.; Garza-Veloz, I.; Castruita-De la Rosa, C.; Ramirez-Acuna, J.M.; Perez-Romero, B.A.; Guerrero-Rodriguez, J.F.; Martinez-Avila, N.; Martinez-Fierro, M.L. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int. J. Mol. Sci. 2020, 21, 9739. [CrossRef] [PubMed]

6. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 2016, 1, 15004. [CrossRef]

7. Beck-Schimmer, B.; Breitenstein, S.; Bonvini, J.M.; Lesurtel, M.; Ganter, M.; Weber, A.; Puhan, M.A.; Clavien, P.A. Protection of pharmacological postconditioning in liver surgery: Results of a prospective randomized controlled trial. Ann. Surg. 2012, 256, 837–845; discussion 835–844. [CrossRef] [PubMed]

8. Liang, T.Y.; Peng, S.Y.; Ma, M.; Li, H.Y.; Wang, Z.; Chen, G. Protective effects of sevoflurane in cerebral ischemia reperfusion injury: A narrative review. Med. Gas Res. 2021, 11, 152–154. [PubMed]

9. Guerrero Orrich, J.L.; Escalona Belmonte, J.J.; Ramirez Aliaq, M.; Ramirez Fernandez, A.; Raigon Ponferrada, A.; Rubio Navarro, M.; Cruz Manas, J. Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope. Curr. Med. Chem. 2020, 27, 2147–2160. [CrossRef]

10. Stollings, L.M.; Jia, L.J.; Tang, P.; Dou, H.; Lu, B.; Xu, Y. Immune Modulation by Volatile Anesthetics. Anesthesiology 2016, 125, 399–411. [CrossRef]

11. Yuki, K.; Eckenhoff, R.G. Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review. Anesth. Analg. 2016, 123, 326–335. [CrossRef] [PubMed]

12. Muller-Edenborn, B.; Frick, R.; Piegeler, T.; Schlaper, M.; Roth-Z’graggen, B.; Schlicker, A.; Beck-Schimmer, B. Volatile anaesthetics reduce neutrophil inflammatory response by interfering with CXCR-2 signalling. Br. J. Anaesth. 2015, 114, 143–149. [CrossRef] [PubMed]

13. Ciechanowicz, S.; Zhao, H.; Chen, Q.; Cui, J.; Mi, E.; Mi, E.; Lian, Q.; Ma, D. Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro. Br. J. Anaesth. 2018, 120, 368–375. [CrossRef]

14. Iwasaki, M.; Zhao, H.; Jaffer, T.; Unwith, S.; Benzonana, L.; Lian, Q.; Sakamoto, A.; Ma, D. Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. Oncotarget 2016, 7, 26042–26056. [CrossRef]

15. Luo, X.; Zhao, H.; Hennah, L.; Ning, J.; Liu, J.; Tu, H.; Ma, D. Impact of isoflurane on malignant capability of ovarian cancer in vitro. Br. J. Anaesth. 2015, 114, 831–839. [CrossRef] [PubMed]

16. Muller-Edenborn, B.; Roth-Z’graggen, B.; Bartsch, K.; Borgeat, A.; Hoos, A.; Borsig, L.; Beck-Schimmer, B. Volatile anaesthetics reduce invasion of colorectal cancer cells through down-regulation of matrix metalloproteinase-9. Anesthesiology 2012, 117, 293–301. [CrossRef] [PubMed]
17. Jiang, S.; Liu, Y.; Huang, L.; Zhang, F.; Kang, R. Effects of propofol on cancer development and chemotherapy: Potential mechanisms. *Eur. J. Pharmacol.* 2018, 831, 46–51. [CrossRef]

18. Wang, Z.T.; Gong, H.Y.; Zheng, F.; Liu, D.J.; Dong, T.L. Propofol suppresses proliferation and invasion of pancreatic cancer cells by upregulating microRNA-133a expression. *Genet. Mol. Res.* 2015, 14, 7529–7537. [CrossRef]

19. Du, Q.H.; Xu, Y.B.; Zhang, M.Y.; Yun, P.; He, C.Y. Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of natural factor-kappaB activity. *World J. Gastroenterol.* 2013, 19, 5485–5492. [CrossRef]

20. Su, Z.; Hou, X.K.; Wen, Q.P. Propofol induces apoptosis of epithelial ovarian cancer cells by upregulation of microRNA let-7i expression. *Eur. J. Gynaecol. Oncol.* 2014, 35, 688–691.

21. Huang, X.; Teng, Y.; Yang, H.; Ma, J. Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-kappaB signal. *Braz. J. Med. Biol. Res.* 2016, 49, e5717. [CrossRef]

22. Wang, P.; Chen, J.; Mu, L.H.; Du, Q.H.; Niu, X.H.; Zhang, M.Y. Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. *Eur. Rev. Med. Pharmacol. Sci.* 2013, 17, 1722–1729.

23. Zhang, J.; Wu, G.Q.; Zhang, Y.; Feng, Z.Y.; Zhu, S.M. Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression. *Cell Biol. Int.* 2013, 37, 227–232. [CrossRef] [PubMed]

24. Zhang, J.; Zhang, D.; Wu, G.Q.; Feng, Z.Y.; Zhu, S.M. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. *Hepatobiliary Pancreat. Dis. Int.* 2013, 12, 305–309. [CrossRef]

25. Wu, K.C.; Yang, S.T.; Hsia, T.C.; Yang, J.S.; Chiou, S.M.; Lu, C.C.; Wu, R.S.; Chung, J.G. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. *Anticancer Res.* 2012, 32, 4833–4842. [PubMed]

26. Yang, N.; Liang, Y.; Yang, P.; Ji, F. Propofol suppresses LPS-induced nuclear accumulation of HIF-1alpha and tumor aggressiveness in non-small cell lung cancer. *Oncol. Rep.* 2017, 37, 2611–2619. [CrossRef]

27. Zheng, X.; Dong, L.; Zhao, S.; Li, Q.; Liu, D.; Zhu, X.; Ge, X.; Li, R.; Wang, G. Propofol Affects Non-Small-Cell Lung Cancer Cell Biology By Regulating the miR-21/PTEN/AKT Pathway In Vitro and In Vivo. *Anesth. Analg.* 2020, 131, 1270–1280. [CrossRef]

28. Liu, Q.; Sheng, Z.; Cheng, C.; Zheng, H.; Lanuti, M.; Liu, R.; Wang, P.; Shen, Y.; Xie, Z. Anesthetic Propofol Promotes Tumor Metastasis in Lungs via GABAA R-Dependent TRIM21 Modulation of Src Expression. *Adv. Sci.* 2021, 8, e2102079. [CrossRef]

29. Guarino, M. Src signaling in cancer invasion. *J. Cell. Physiol.* 2010, 223, 14–26. [CrossRef]

30. Jiang, W.; Xu, Z.; Yu, L.; Che, J.; Zhang, J.; Yang, J. MicroRNA-144-3p suppressed TGF-beta1-induced lung cancer cell invasion and adhesion by regulating the Src-Akt-Erk pathway. *Cell Biol. Int.* 2019, 43, 51–61. [CrossRef] [PubMed]

31. Yu, B.; Gao, W.; Zhou, H.; Miao, X.; Chang, Y.; Wang, L.; Xu, M.; Ni, G. Propofol induces apoptosis of breast cancer cells by downregulation of miR-24 signal pathway. *Cancer Biomark.* 2018, 21, 513–519. [CrossRef] [PubMed]

32. Garib, V.; Lang, K.; Niggemann, B.; Zanker, K.S.; Brandt, L.; Dittmar, T. Propofol-induced calcium signalling and actin reorganization within breast carcinoma cells. *Eur. J. Anaesthesiol.* 2005, 22, 609–615. [CrossRef] [PubMed]

33. Meng, C.; Song, L.; Wang, J.; Li, D.; Liu, Y.; Cui, X. Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231. *Oncol. Rep.* 2017, 37, 841–848. [CrossRef] [PubMed]

34. Wu, Z.F.; Lee, M.S.; Wong, C.S.; Lu, C.H.; Huang, Y.S.; Lin, K.T.; Lou, Y.S.; Lin, C.; Chang, Y.C.; Lai, H.C. Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery. *Anesthesiology* 2018, 129, 932–941. [CrossRef]

35. Jun, I.J.; Jo, J.Y.; Kim, J.I.; Chin, J.H.; Kim, W.J.; Kim, H.R.; Lee, E.H.; Choi, I.C. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study. *Sci. Rep.* 2017, 7, 14020. [CrossRef]

36. Lai, H.C.; Lee, M.S.; Lin, C.; Lin, K.T.; Huang, Y.H.; Wong, C.S.; Chan, S.M.; Wu, Z.F. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatopathy for hepatocellular carcinoma: A retrospective cohort study. *Br. J. Anaesth.* 2019, 123, 151–160. [CrossRef]

37. Lai, H.C.; Lee, M.S.; Lin, K.T.; Huang, Y.H.; Chen, J.Y.; Lin, Y.T.; Hung, K.C.; Wu, Z.F. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in robot-assisted radical prostatectomy. *PLoS ONE* 2020, 15, e0230290. [CrossRef]

38. Enlund, M.; Berglund, A.; Ahlstrand, R.; Wallden, J.; Lundberg, J.; Warnberg, F.; Ekman, A.; Sjöblom Widfeldt, N.; Enlund, A.; Bergkvist, L. Survival after primary breast cancer surgery following propofol or sevoflurane general anaesthesia-A retrospective, multicenter, database analysis of 6305 Swedish patients. *Acta Anaesthesiol. Scand.* 2020, 64, 1048–1054. [CrossRef]

39. Lee, J.H.; Kang, S.H.; Kim, Y.; Kim, H.A.; Kim, B.S. Effects of propofol-based total intravenous anaesthesia on recurrence and overall survival in patients after modified radical mastectomy: A retrospective study. *Korean J. Anesthesiol.* 2016, 69, 126–132. [CrossRef]

40. Hasselager, R.P.; Hallas, J.; Gogenen, I. Inhalation or total intravenous anaesthesia and recurrence after colorectal cancer surgery: A propensity score matched Danish registry-based study. *Br. J. Anaesth.* 2021, 126, 921–930. [CrossRef]
41. Oh, T.K.; Kim, K.; Jheon, S.; Lee, J.; Do, S.H.; Hwang, J.W.; Song, I.A. Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis. *Cancer Control*. 2018, 25, 1073274818775360. [CrossRef]

42. Kim, M.H.; Kim, D.W.; Kim, J.H.; Lee, K.Y.; Park, S.; Yoo, Y.C. Does the type of anesthesia really affect the recurrence-free survival after breast cancer surgery? *OncoTarget* 2017, 8, 90477–90487. [CrossRef]

43. Yoo, S.; Lee, H.B.; Han, W.; Noh, D.Y.; Park, S.K.; Kim, W.H.; Kim, J.T. Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study. *Anesthesiology* 2019, 130, 31–40. [CrossRef]

44. Kim, R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. *J. Transl. Med.* 2018, 16, 8. [CrossRef] [PubMed]

45. O’Bryan, L.J.; Atkins, K.J.; Lipszyc, A.; Scott, D.A.; Silbert, B.S.; Evered, L.A. Inflammatory Biomarker Levels After Propofol or Sevoflurane Anesthesia: A Meta-analysis. *Anesth. Analg.* 2022, 134, 69–81. [CrossRef] [PubMed]

46. Wigmore, T.J.; Mohammed, K.; Jhanji, S. Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis. *Anesthesiology* 2016, 124, 69–79. [CrossRef] [PubMed]

47. Yap, A.; Lopez-Olivo, M.A.; Dubowitz, J.; Hiller, J.; Riedel, B.; Global Onco-Anesthesia Research Collaboration Group. Anesthetic technique and cancer outcomes: A meta-analysis of total intravenous versus volatile anesthesia. *Can. J. Anaesth. = J. Can. D’anesthesie* 2019, 66, 546–561. [CrossRef]

48. Oh, C.S.; Lee, J.; Yoon, T.G.; Seo, E.H.; Park, H.J.; Piao, L.; Lee, S.H.; Kim, S.H. Effect of Equipotent Doses of Propofol versus Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. *Anesthesiology* 2018, 129, 921–931. [CrossRef]

49. Yan, T.; Zhang, G.H.; Wang, B.N.; Sun, L.; Zheng, H. Effects of propofol/remifentanil-based total intravenous anestheisa versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-beta and prognosis after breast cancer surgery: A prospective, randomized and controlled study. *BMC Anesthesiol.* 2018, 18, 131. [CrossRef]

50. Castro-Giner, F.; Aceto, N. Tracking cancer progression: From circulating tumor cells to metastasis. *Genome Med.* 2020, 12, 31. [CrossRef]

51. Zhong, Y.; Ma, T.; Qiao, T.; Hu, H.; Li, Z.; Luo, K.; Wang, Y.; Tang, Q.; Wang, G.; Huang, R.; et al. Role of Phenotypes of Circulating Tumor Cells in the Diagnosis and Treatment of Colorectal Cancer. *Cancer Manag. Res.* 2021, 13, 7077–7085. [CrossRef] [PubMed]

52. Yang, M.; Zhang, X.; Guo, L.; Liu, X.; Wu, J.; Zhu, H. Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment. *BioMed Res. Int.* 2021, 2021, 6230826. [CrossRef] [PubMed]

53. Liu, D.; Mao, Y.; Ma, H. Value of circulating tumor cells in the diagnosis and treatment of solitary pulmonary nodules. *Ann. Transl. Med.* 2021, 9, 501. [CrossRef] [PubMed]

54. Hovaguimian, F.; Braun, J.; Z’Graggen, B.R.; Schlaper, M.; Dumrese, C.; Ewald, C.; Dedes, K.J.; Fink, D.; Rolli, U.; Seeberger, M.; et al. Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial. *Anesthesiology* 2020, 133, 548–558. [CrossRef] [PubMed]